Berkshire Hathaway: Start of a New Double-Compounding Cycle — Time to Buy the A-Share

Hook & thesis

Berkshire Hathaway is no longer content to sit on its mountain of cash. Management has pivoted: Q2 2026 saw $31 billion of deployment, including a $17 billion purchase of Alphabet, fresh stakes in Delta Air Lines and Macy's, and a resumption of buybacks ($4.53 billion). That operational shift matters: when a high-quality conglomerate with durable insurance float and steady industrial earnings starts redeploying capital at sensible prices, you get a two-headed compounding effect — operating earnings compounding and faster per-share earnings growth from share retirements.

My trade idea: take a long position in Berkshire Hathaway A shares at $761,245 with a clear stop and a 180-trading-day target. The valuation is reasonable — market cap near $1.09 trillion, price-to-earnings roughly 12.6x and price-to-book around 1.45x — and the balance sheet gives management the optionality to accelerate returns if markets wobble. Momentum indicators are supportive (MACD bullish, RSI neutral), and short interest is trivial versus average volume, limiting the risk of a sharp squeeze-driven reversal.

What Berkshire does and why the market should care

Berkshire Hathaway is a diversified holding company with dominant insurance operations (GEICO, BH Primary and Reinsurance), a major railroad (BNSF), regulated utilities (BHE), travel centers, manufacturing, wholesale distribution (McLane), and retail/service businesses. Those businesses produce steady operating earnings and a recurring float that funds investments.

The market should care because the company pairs a fortress balance sheet with an unusually long leash for opportunistic capital deployment. With $366 billion of cash on the balance sheet after Q2's activity, management can underwrite insurance risk, invest in public equities, buy entire businesses, or repurchase shares — and right now they're doing more of all of the above. That changes the returns profile: instead of cash dragging performance, capital becomes an active lever for EPS and intrinsic value growth.

Supporting numbers

Valuation framing

At roughly 12.6x trailing earnings and 1.45x book, Berkshire trades like a high-quality conglomerate with embedded optionality — cheaper than many single-line financials and far cheaper than many growth names that lack insurance float or industrial earnings. Historically, Berkshire has warranted a premium because of its capital allocation track record; today that premium is muted because much of the company's value sits in cash and public equities while buybacks were paused for 21 months. Now buybacks have resumed and capital is being actively deployed, which should help justify and expand per-share intrinsic value over the coming quarters.

Look at the math: even modest operating earnings growth (mid-single digits) plus ongoing buybacks that retire shares at sub-intrinsic-value prices will accelerate EPS growth. Management has already retired nearly 13% of outstanding shares since mid-2018 and returned over $82 billion to shareholders via repurchases and M&A since 07/15/2018 — that matters when you own a large, slowly compounding enterprise.

Catalysts (what can lift the stock)

• Continued buybacks: management signaled a willingness to spend more than the $4.53B in Q2; continued, disciplined repurchases will accelerate EPS per share.
• Large-scale investments and tuck-ins: further deployments into public equities or acquisitions bought at attractive prices can create step-change value.
• Beat-and-raise earnings cadence: operating earnings were +16.3% YoY in Q2; continued cross-segment growth (insurance underwriting, BNSF volumes, utilities) will push intrinsic earnings higher.
• Market dislocations: if macro volatility deepens, Berkshire's $366B cash stockpile gives it first-mover advantage to buy high-quality assets cheaply.

Trade plan (actionable)

Entry: Buy BRK.A at $761,245 (market entry acceptable given low intraday liquidity of A-shares).
Target: $825,000 (exit on move to target within long-term horizon).
Stop: $705,000 (hard stop to limit downside and respect the stock's 52-week low proximity).
Horizon: long term (180 trading days). I choose 180 trading days because capital redeployment and buyback-driven EPS effects are not instantaneous — they compound over months. Expect visible EPS lift and clearer capital allocation trends within one to two quarters, with the market digesting buyback cadence and large investments across the 180-day window.

Position sizing note: Berkshire A-shares are illiquid relative to most large-cap names; use limit orders and stagger entries if deploying a sizable allocation. Keep position size consistent with a medium-risk profile (no more than a single-digit percentage of a diversified equity sleeve for most retail portfolios).

Risks and counterarguments

• Macro valuation re-rating - If equity markets correct deeply and sentiment toward value cyclicals collapses, Berkshire may trade down despite intrinsic strength; cash deployment may not offset a market-wide sell-off.
• Large capital missteps - Deploying chunks of the $366B cash at poor prices (paying too much for acquisitions or stock purchases) would impair future returns.
• Insurance volatility - Significant catastrophe losses or an underwriting cycle deterioration could drain float and force capital conservatism, hitting earnings.
• Railroad / industrial cyclicality - BNSF volumes and manufacturing demand are cyclically sensitive; an unexpected slowdown could depress operating earnings.
• Execution & governance risk - While Greg Abel is established as CEO, large conglomerates can suffer from opportunistic acquisitions or poor integration, which would reduce the expected compounding effect.

Counterargument: One coherent counterargument is that Berkshire's structural advantage was its ability to accumulate cash and wait for fire-sale prices. As markets normalize and cash is consumed for large public stakes (for example, a $17B Alphabet purchase), the optionality of holding a dry powder buffer diminishes. If management spends aggressively into expensive assets or fails to find bargains, the company could trade more like an active allocator than a deep-value fortress, blunting returns and making the stock vulnerable to a multiple compression.

What would change my mind

I would re-evaluate the bullish stance if any of the following occur: 1) Management pivots to large-scale deployments at clearly elevated prices instead of opportunistic buys; 2) Q3/Q4 operating earnings show signs of structural decline (insurance underwriting losses or steep BNSF weakness) rather than cyclical softness; 3) buybacks slow materially or the company issues equity; or 4) the cash balance falls rapidly without visible value-creating deployment (i.e., cash is burned on overpriced transactions).

Conclusion

Berkshire Hathaway today looks like a classic capital-allocation story re-accelerating into action. With a $366B war chest, management has begun redeploying cash and has resumed buybacks — and those two levers together create a 'double compounding' effect: steady operating earnings growth plus faster EPS growth through share retirements. At ~12.6x earnings and 1.45x book, the valuation gives a cushion that makes a long position attractive for disciplined investors willing to hold for the next 180 trading days.

Trade entry at $761,245, target $825,000, stop $705,000. Monitor buyback cadence, cash balance changes, and operating earnings across insurance, BNSF and utilities. If management starts overpaying for assets or operating results deteriorate, tighten stops or exit.

In short: the setup is favorable for long exposure, but this is an active trade that requires monitoring capital deployment quality as the primary value driver going forward.